Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC
Clinical trial NCT04926831 · TERMINATED
Trial details
- NCT number
- NCT04926831
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-10
- Primary completion
- 2024-03-13
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.